CCSG developmental funds leveraged additional institutional support and provided an exceptionally strong return on investment. The $350,000 CCSG support of the New Investigator Award Program was supplemented by $80,000 of institutional/philanthropic funds, allocated to eight new faculty recruits, and generated a total of $9 million (total costs) in grant support. The $1.2 million CCSG support of the Pilot Project Program was supplemented by $1.5 million of institutional/philanthropic funds, generating $17.8 million (total costs) in grant support. The grand total of $26.8 million return on investment (ROI) includes over $26.6 million in peer reviewed grant support, and represents a 17.5-fold ROI of CCSG funds invested for New Investigator Awards and Pilot Projects. CCSG developmental funds further enabled shared resource evolution. The Metabolomics shared resource has matured to an established shared resource that offers unique technical expertise and ease-of-access to state-of-the-art instrumentation and current protocols that are not available in most individual investigator laboratories; this resource continues to fuel collaborative research with Princeton University and over a recent twelve-month period, served 19 investigators (17 of whom are CINJ members) across three CINJ programs. Given the continued substantial growth of the CINJ research enterprise, and the successful use of developmental funds in the current project period, we request $425,000 per year to be used in three categories: 1) recruitment of investigators in areas of strategic priority for CINJ (New Investigator Award program), 2) development of new shared resources in Immune Monitoring (responding to the Director?s initiative in Immune Oncology) and Small Molecule Screening (critical to all Basic programs and specifically responsive to a 2011 critique of the Cancer Pharmacology Program), and 3) pilot awards (Pilot Project program) to promote novel, collaborative research aligned with strategic priorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112884
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23

Showing the most recent 10 out of 775 publications